7 unknown, 5 completed, 3 not yet recruiting, 2 suspended. 11 Phase 1, 10 Phase 2, 1 Early Phase 1.
Follow B-cell Non-Hodgkin's Lymphoma: new trials by email Literature Review of B-cell Non-Hodgkin's Lymphoma trials Research Report on B-cell Non-Hodgkin's Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma JS203 in combination with gemcitabine and oxaliplatin, JS203 in combination with ifosfamide, carboplatin and etoposide, JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone - B-cell Non-Hodgkin's Lymphoma | Phase 2 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 180 | 2025-08-17 | 2026-09-04 |
| A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies RS001 injection - B-cell Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | Guangdong Ruishun Biotech Co., Ltd | 13 | 2025-04-01 | 2025-03-25 |
| A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL RJMty19 (CD19-CAR-DNT cells) - B-cell Non-Hodgkin's Lymphoma | Phase 1 | Not yet recruiting | Guangdong Ruishun Biotech Co., Ltd | 30 | 2024-05-20 | 2024-03-18 |
| A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma SHR-A1912; R-Chemo - B-cell Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | Shanghai Hengrui Pharmaceutical Co., Ltd. | 132 | 2023-11-17 | 2023-12-27 |
| A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide IMM0306, Lenalidomide capsule - B-cell Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 102 | 2023-05-01 | 2023-05-24 |
| Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL CD19-CAR-DNT cells - B-cell Non-Hodgkin's Lymphoma | Phase 1 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 12 | 2022-06-15 | 2022-07-12 |
| Long-Term Follow-up Study Caribou-sponsored investigational therapy - Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma | Enrolling by invitation | Caribou Biosciences, Inc. | 150 | 2022-03-16 | 2026-03-12 | |
| CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. CD19/CD20 Dual-CAR-T cells - B-cell Non-Hodgkin's Lymphoma | Early Phase 1 | Suspended | Beijing Tsinghua Chang Gung Hospital | 12 | 2022-03-10 | 2022-02-14 |
| HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma HMPL-760 - B-Cell Non-Hodgkin's Lymphoma | Phase 1 | Completed | Hutchmed | 89 | 2022-01-04 | 2025-04-09 |
| A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection - B-cell Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Nanjing IASO Biotechnology Co., Ltd. | 125 | 2021-10-20 | 2021-10-25 |
| Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma Human CD19Targeted T Cells Injection - B-cell Non-Hodgkin's Lymphoma | Phase 2 | Unknown | Hrain Biotechnology Co., Ltd. | 100 | 2021-08-09 | 2022-07-05 |
| Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL) IMM0306 - B-cell Non-Hodgkin's Lymphoma | Phase 1 | Suspended | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 90 | 2021-01-15 | 2022-09-26 |
| A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma Prizloncabtagene Autoleucel - B-cell Non-Hodgkin's Lymphoma | Phase 1 | Completed | Peking Union Medical College Hospital | 10 | 2020-10-30 | 2025-05-23 |
| Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226) GB226 - B-cell Non-Hodgkin's Lymphoma | Phase 2 | Unknown | Genor Biopharma Co., Ltd. | 53 | 2018-10-15 | 2021-03-03 |
| Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) Chidamide plus DICE Regimen - B-cell Non-Hodgkin's Lymphoma | Phase 2 | Unknown | Peking University | 46 | 2017-04-11 | 2017-04-11 |
| Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL Debio 1562, Rituximab - Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma | Phase 2 | Completed | Debiopharm International SA | 100 | 2016-06-05 | 2024-06-12 |
| Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma Bendamustine, Pentostatin, Ofatumumab - Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin's Lymphoma | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 10 | 2011-05-25 | 2025-04-29 |
| A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma KW-2478 - Multiple Myeloma, Chronic Lymphocytic Leukaemia | Phase 1 | Completed | Kyowa Kirin Co., Ltd. | 27 | 2007-04-01 | 2024-04-25 |
| Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) Cyclophosphamide, Pentostatin, Rituximab - Immunocytoma/Morbus Waldenström, B-Cell Non-Hodgkin's Lymphoma | Phase 2 | Unknown | Heidelberg University | 185 | 2005-02-01 | 2009-06-25 |
| Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant - Lymphoma, B-cell Non-Hodgkin's Lymphoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 20 | 2003-10-01 | 2015-12-04 |
Lymphoma, B-Cell (20) · Lymphoma (4) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Neoplasms (2) · Bronchiolitis Obliterans Syndrome (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Leukemia, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Large B-Cell, Diffuse (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (20) · Immune System Diseases (20) · Immunoproliferative Disorders (20) · Lymphatic Diseases (20) · Lymphoproliferative Disorders (20) · Neoplasms by Histologic Type (20) · Lymphoma, Non-Hodgkin (18) · Neoplasms (18) · Lymphoma (16) · Hematologic Diseases (4) · Leukemia, Lymphoid (4) · Disease Attributes (3) · Leukemia (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3)
Rituximab (4) · Carboplatin (2) · Cyclophosphamide (2) · Etoposide (2) · Ifosfamide (2) · Lenalidomide (2) · Pentostatin (2) · Bendamustine Hydrochloride (1) · Doxorubicin (1) · Filgrastim (1) · Gemcitabine (1) · Granulocyte Colony-Stimulating Factor (1) · KW-2478 (1) · Mesna (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1)
Guangdong Ruishun Biotech Co., Ltd (2) · ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (2) · Beijing Tsinghua Chang Gung Hospital (1) · Caribou Biosciences, Inc. (1) · Debiopharm International SA (1) · Genor Biopharma Co., Ltd. (1) · Heidelberg University (1) · Hrain Biotechnology Co., Ltd. (1) · Hutchmed (1) · Kyowa Kirin Co., Ltd. (1) · Memorial Sloan Kettering Cancer Center (1) · Nanjing IASO Biotechnology Co., Ltd. (1) · Peking Union Medical College Hospital (1) · Peking University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
China (8) · United States (5) · Belgium (1) · Bulgaria (1) · Czechia (1) · Hungary (1) · Italy (1) · Poland (1) · Switzerland (1) · Ukraine (1) · United Kingdom (1)
Anthony D Ho, Ph.D., Prof. (1) · Cheng Huang, MD (1) · Craig Moskowitz, MD (1) · Daobin Zhou, PhD&MD (1) · J D Cavenagh, MD. MRCP, MRCPath (1) · Jo Fili, MD (1) · Jun Zhu, MD (1) · JunYuan Qi, MD, PHD (1) · Peng Liu, M.D. & Ph.D. (1) · Weili Zhao, Ph.D (1) · Wenbin Qian, MD, PhD (1) · Yuankai Shi, Doctor (1)
2015 (1)